2,4-双(三氟甲基)苯甲酸 | 32890-87-2

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-双(三氟甲基)苯甲酸
• 中文别名: 2,3-二甲基-5-丙基吡嗪；2,4-二三氟甲基苯甲酸；2,4-二(三氟甲基)苯甲酸
• 英文名称: 2,4-bis(trifluoromethyl)benzoic acid
• CAS: 32890-87-2
• 化学式: C₉H₄F₆O₂
• mdl: MFCD00042496
• 分子量: 258.12
• InChiKey: JTOIZLCQNWWDCN-UHFFFAOYSA-N

物化性质

• 熔点：
  109-111 °C(lit.)
• 沸点：
  219℃
• 密度：
  1.527
• 闪点：
  86℃
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会发生分解，也没有已知的危险反应。 应避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2916399090

SDS

Name:	2 4-Bis(trifluoromethyl)benzoic acid 98% Material Safety Data Sheet
Synonym:
CAS:	32890-87-2

Section 1 - Chemical Product MSDS Name:2 4-Bis(trifluoromethyl)benzoic acid 98% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
32890-87-2	2,4-Bis(trifluoromethyl)benzoic acid	98	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Chronic inhalation and ingestion may cause chronic fluoride poisoning (fluorosis) characterized by weight loss, weakness, anemia, brittle bones, and stiff joints. Chronic exposure to fluoride compounds may cause systemic toxicity.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid breathing dust.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 32890-87-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 109 - 111 deg C
Autoignition Temperature: Not available.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: slightly soluble
Specific Gravity/Density:
Molecular Formula: (CF3)2C6H3CO2H
Molecular Weight: 258.12

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 32890-87-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,4-Bis(trifluoromethyl)benzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 32890-87-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 32890-87-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 32890-87-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学反应

2,4-双(三氟甲基)苯甲酸是一种含氟的苯甲酸，因其结构上含有羧基，具有一定的酸性，可以发生酯化反应。

合成方法

将庚烷中的二丁基镁溶液（0.9M，10mmol，11ml）在真空和室温下滴入1,3-双三氟甲基苯（2.14g，10mmol）的乙醚（10ml）溶液中。将此反应液冷却至0°C，并加入正丁基锂的己烷溶液（2.5M，10mmol，4ml）。在20°C下保持反应混合物4小时后，将其倒入固体二氧化碳并剧烈搅拌。然后在室温条件下放置，用0.1M HCl酸化至pH 1-2。使用二氯甲烷萃取所得反应混合物，并分离有机相。再用10%NaOH水溶液萃取有机相，随后将碱性水萃取物用HCl酸化至pH 1.2，然后用二氯甲烷进一步萃取所述水层中的物质。最终得到的有机萃取物用水洗涤并用硫酸钠干燥。在真空下蒸发溶剂后，得到2,4-双(三氟甲基)苯甲酸（1.8g），沸点为107-109°C。通过1H-NMR（CDCl3）分析其结构：δ（ppm）7.95 （m，1H）， 8.06 （m，1H）， 8.12 （m，1H）， 11.8 （broad，1H）。

反应信息

• 作为反应物：
  描述：

  2,4-双(三氟甲基)苯甲酸 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 反应 16.0h， 生成 2,4-二三氟甲基苯酚
  参考文献：
  名称：

  苯甲酸的脱羧羟基化

  摘要：

  在此，报道了第一个由苯甲酸合成苯酚的脱羧羟基化反应。该方法克服了与传统苯甲酸脱羧相关的挑战，甚至可以应用于后期功能化。

  DOI：

  10.1002/anie.202108971
• 作为产物：
  描述：

  以 乙醇 、 二氯甲烷 为溶剂， 生成 2,4-双(三氟甲基)苯甲酸
  参考文献：
  名称：

  估算S N 1速率常数的方法：苯甲酸酯的溶剂化反应性

  摘要：

  五氟苯甲酸酯（PFB）和2,4,6-三氟苯甲酸酯（TFB）离开基团的核官能度是通过应用LFER方程从在一系列水性溶剂中测量的X，Y取代的苯甲基PFB和TFB的溶剂分解速率常数得出的：log k = s f（E f + N f）。二苯胺基甲基PFB和TFB的杂解速率常数，以及在乙醇水溶液中另外10种苯甲酰甲基苯甲酸酯的杂化速率常数，构成了一组参考苯甲酸酯，其实验ΔG with与ΔH correlat相关。（通过PCM量子化学方法计算）模型环氧环的形成。由于具有极好的相关性（r = 0.997），因此已经建立了计算取代苯甲酸酯LG的核官能度的方法，最终提供了一种测定给定溶剂中任何苯甲酸酯的S N 1反应性的方法。使用Δ ģ ⧧ VSΔ ħ ⧧的相关性，并考虑小号˚F基于相似性，已在90％，80％和70％的乙醇水溶液中确定了约70种苯甲酸酯的核官能度参数。计算得出的取代苯甲酸酯离去基团的固有壁垒

  DOI：

  10.1021/jo3013308

文献信息

• [EN] CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES CARBOCYCLIQUES DU RÉCEPTEUR GLYT1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011023667A1

  公开（公告）日：2011-03-03

  The present invention relates to the use of a compound of general formula (I) wherein R1/R2 are independently from each other hydrogen, lower alkyl, -CH2)o-cycloalkyl for o being 0 or 1, or are benzyl or heterocycloalkyl; or R1 and R2 are together with the N-atom to which they are attached a ring containing -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2-S-(CH2)2-, -(CH2)2-NR-(CH2)2-, -(CH2)2-C(O)-(CH2)2-, -(CH2)2-CF2-(CH2)2-, -CH2-CHR-(CH2)2, -CHR-(CH2)3, CHR-(CH2)2-CHR-, or is the ring 2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester and R is hydroxy, halogen, cycloalkyl, or C(O)O-lower alkyl; X is -(CH2)4-, -(CH2)3-, -(CH2)2- or -CH2-; R3 is S-lower alkyl, CF3, OCHF2, lower alkoxy, lower alkyl, phenyl, cycloalkyl or halogen; R4 is CF3, lower alkoxy, lower alkyl, halogen and n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers thereof for the manufacture of a medicament for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

  本发明涉及一种通式(I)的化合物的使用，其中R1/R2分别独立地为氢、较低的烷基、-CH2)o-环烷基，其中o为0或1，或者为苄基或杂环烷基；或者R1和R2与它们连接的N原子一起形成一个含有-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)2-O-(CH2)2-、-(CH2)2-S-(CH2)2-、-(CH2)2-NR-(CH2)2-、-(CH2)2-C(O)-(CH2)2-、-(CH2)2-CF2-(CH2)2-、-CH2-CHR-(CH2)2、-CHR-(CH2)3、CHR-(CH2)2-CHR-的环，或者是环2,6-二氮杂螺[3.3]庚烷-2-羧酸叔丁基酯，R为羟基、卤素、环烷基或C(O)O-较低烷基；X为-(CH2)4-、-(CH2)3-、-(CH2)2-或-CH2-；R3为S-较低烷基、CF3、OCHF2、较低烷氧基、较低烷基、苯基、环烷基或卤素；R4为CF3、较低烷氧基、较低烷基、卤素，n为1或2；或者用于制备用于治疗精神病、疼痛、记忆和学习功能障碍、注意力缺陷、精神分裂症、痴呆症或阿尔茨海默病的药物的药学上可接受的酸盐、外消旋混合物或其相应的对映体和/或光学异构体。
• [EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013018929A1

  公开（公告）日：2013-02-07

  The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种新型的化合物，作为一种ERR-α调节剂具有优越的活性，并可作为预防或治疗与ERR-α相关疾病的药物。本发明涉及一种由公式(1)表示的化合物，其中每个符号如说明书中所定义，或其盐。
• 6,6′-Aryl trehalose analogs as potential Mincle ligands
  作者：Omer K. Rasheed、George Ettenger、Cassandra Buhl、Robert Child、Shannon M. Miller、Jay T. Evans、Kendal T. Ryter

  DOI：10.1016/j.bmc.2020.115564

  日期：2020.7

  6,6′-Aryl trehalose derivatives have been synthesized with a view towards identifying novel Th-17-inducing vaccine adjuvants based on the high affinity Mincle ligand Brartemicin. The initial structure-activity relationships of these novel trehalose-based compounds were investigated. All compounds have been evaluated for their ability to engage the Mincle receptor and induce a potential pro-Th17 cytokine

  已经合成了 6,6'-芳基海藻糖衍生物，以鉴定基于高亲和力 Mincle 配体 Brartemicin 的新型 Th-17 诱导疫苗佐剂。研究了这些新型海藻糖基化合物的初始构效关系。根据人外周血单核细胞中 IL-6 的产生，所有化合物都已评估了它们参与 Mincle 受体的能力，并诱导人外周血单核细胞产生潜在的前 Th17 细胞因子谱。本文中介绍的设计类似物的初步生物学表征将有助于未来设计和测试更多的仿射配体，这可能会促进发现具有改进药理特性的新型佐剂。
• PIPERIDINE DERIVATIVES
  申请人：Kolczewski Sabine

  公开号：US20100197715A1

  公开（公告）日：2010-08-05

  The present invention relates to a compound of formula I wherein R 1 , R 2 , and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. These compounds and their pharmaceutical compositions are useful in the treatment of neurological and neuropsychiatric disorders.

  本发明涉及式I的化合物，其中R1、R2和Ar定义如本文中所述，或涉及一种药物可接受的酸性加成盐，或涉及其相应的对映体和/或光学异构体。这些化合物及其药物组合物可用于治疗神经和神经精神障碍。
• CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS
  申请人：Kolczewski Sabine

  公开号：US20110053904A1

  公开（公告）日：2011-03-03

  The present invention relates to the use of a compound of formula I wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

  本发明涉及使用式I的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，X和n如本文所定义 或其药学上可接受的酸盐，或其相应的对映体和/或光学异构体，用于治疗精神病、疼痛、记忆和学习功能障碍、注意力缺陷、精神分裂症、痴呆症或阿尔茨海默病。

表征谱图